Key Takeaways:
- Generic liraglutide became the first GLP-1 with generic availability for both diabetes and obesity indications in late 2025
- Brand Victoza remains on shortage while generic supply is improving but still scaling in early 2026
- The availability of generic options represents a meaningful step forward for patient access and affordability
The First Generic GLP-1 Breaks New Ground
A historic milestone has quietly unfolded in the GLP-1 market: generic liraglutide became the first GLP-1 with generic availability for both diabetes and obesity indications in late 2025. This development marks the beginning of what could be a major shift toward more affordable GLP-1 treatment options.
Meitheal Pharmaceuticals launched the first generic liraglutide injection in April 2025, approved for type 2 diabetes, marking the first generic GLP-1 receptor agonist on the U.S. market. Teva followed with its own generic liraglutide in mid-2025, creating the first real price competition in the GLP-1 space since these medications began transforming obesity and diabetes treatment.
The significance cannot be overstated. While newer GLP-1s like semaglutide (Wegovy, Ozempic) and tirzepatide (Zepbound, Mounjaro) dominate headlines with their superior weight loss results, patent protection prevents generic competition until approximately 2031–2032 for semaglutide. Liraglutide's generic availability offers the first glimpse of what GLP-1 treatment could cost without patent protection.
Supply Challenges Persist Despite Generic Entry
The transition hasn't been seamless. Novo Nordisk reported ongoing manufacturing delays for brand Victoza, which was placed on FDA shortage status, with brand Victoza remaining on shortage in early 2026. This creates an unusual situation where the generic versions are more readily available than the brand-name original.
Generic supply is improving but still scaling, according to industry reports. For people who need liraglutide specifically — whether due to insurance requirements, dosing needs, or because they've found it works better for them than newer options — this shortage creates real treatment disruptions.
The shortage highlights ongoing manufacturing challenges across the entire GLP-1 class. Surging demand for GLP-1 agonists began in 2022–2023, driven primarily by semaglutide and tirzepatide, creating widespread class-wide shortages, with Novo Nordisk facing production challenges despite investing in manufacturing expansion.
What Generic Competition Means for Your Wallet
Generic liraglutide represents the first real test of whether competition can bring down GLP-1 costs. While specific pricing data wasn't available in our research, the broader GLP-1 pricing landscape remains challenging. Brand-name pricing has remained high at $900–$1,349 per month regardless of shortage status, with Novo Nordisk and Eli Lilly continuing to list Wegovy and Zepbound at $900–$1,300 monthly.
The hope is that generic liraglutide will follow the typical generic drug playbook — significantly lower costs that force brand manufacturers to compete on price. Generic liraglutide is FDA-approved and bioequivalent to Victoza, and given current Victoza supply constraints, switching to generic liraglutide can improve access and reduce costs.
You can compare GLP-1 costs across different pharmacies and insurance plans to find the most affordable option in your area. Generic pricing can vary significantly between locations, making this comparison especially important as more generic versions become available.
Clinical Considerations and Alternative Options
For healthcare providers managing the liraglutide shortage, real-time availability checking at pharmacies near individuals is particularly valuable for practices managing large panels of GLP-1 users and can reduce the time staff spend calling pharmacies on their behalf.
Liraglutide may be less potent than newer GLP-1s, but it remains an important option for many people. It was one of the first GLP-1s proven effective for weight loss and has a long track record of safety. Some people also find they tolerate it better than newer formulations, making the shortage particularly problematic for this population.
For those who can't access liraglutide, switching to other GLP-1 medications like semaglutide or tirzepatide may be an option, though this requires medical supervision and often means starting over with dose titration.
What This Means for You
If you're currently taking liraglutide, you have several options to navigate the ongoing shortage. Generic versions may be more readily available than brand Victoza, and they're FDA-approved as bioequivalent — meaning they work the same way in your body.
Talk with your healthcare provider about switching to generic liraglutide if you're having trouble finding brand Victoza. Many insurance plans actually prefer generics and may have lower copays. You can also compare costs across different pharmacies, as generic pricing can vary significantly between locations.
If liraglutide isn't available in any form, don't stop treatment abruptly. Work with your provider to find an alternative GLP-1 that's covered by your insurance and available at local pharmacies. The telehealth providers in our directory can often help you access alternative medications when local pharmacies are experiencing shortages.
Finding a clinic that stays current on medication availability and generic options can make a significant difference in maintaining consistent treatment. Many providers now track real-time pharmacy stock levels to help you find available medications quickly.
Sources
- Liraglutide Shortage: What Providers and Prescribers Need to Know in 2026 - Comprehensive provider briefing on liraglutide supply status and generic availability
- GLP-1 Shortage Update 2026: What's Available and Your Options - Current availability status across all major GLP-1 medications